Your browser doesn't support javascript.
loading
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
Luzum, J A; Pakyz, R E; Elsey, A R; Haidar, C E; Peterson, J F; Whirl-Carrillo, M; Handelman, S K; Palmer, K; Pulley, J M; Beller, M; Schildcrout, J S; Field, J R; Weitzel, K W; Cooper-DeHoff, R M; Cavallari, L H; O'Donnell, P H; Altman, R B; Pereira, N; Ratain, M J; Roden, D M; Embi, P J; Sadee, W; Klein, T E; Johnson, J A; Relling, M V; Wang, L; Weinshilboum, R M; Shuldiner, A R; Freimuth, R R.
Afiliación
  • Luzum JA; Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
  • Pakyz RE; Center for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
  • Elsey AR; Program for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
  • Haidar CE; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
  • Peterson JF; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Whirl-Carrillo M; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Handelman SK; Department of Biomedical Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Palmer K; Stanford University School of Medicine, Palo Alto, California, USA.
  • Pulley JM; Center for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
  • Beller M; Program for Personalized and Genomic Medicine, School of Medicine, University of Maryland, Baltimore, Maryland, USA.
  • Schildcrout JS; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Field JR; Office of Research Informatics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Weitzel KW; Department of Statistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Cooper-DeHoff RM; Vanderbilt Institute for Clinical and Translational Research, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Cavallari LH; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
  • O'Donnell PH; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
  • Altman RB; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
  • Pereira N; Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
  • Ratain MJ; Stanford University School of Medicine, Palo Alto, California, USA.
  • Roden DM; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota, USA.
  • Embi PJ; Center for Personalized Therapeutics, University of Chicago, Chicago, Illinois, USA.
  • Sadee W; Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.
  • Klein TE; Department of Biomedical Informatics, Ohio State University, Columbus, Ohio, USA.
  • Johnson JA; Center for Pharmacogenomics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
  • Relling MV; Department of Cancer Biology and Genetics, College of Medicine, Ohio State University, Columbus, Ohio, USA.
  • Wang L; Stanford University School of Medicine, Palo Alto, California, USA.
  • Weinshilboum RM; Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA.
  • Shuldiner AR; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Freimuth RR; Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA.
Clin Pharmacol Ther ; 102(3): 502-510, 2017 Sep.
Article en En | MEDLINE | ID: mdl-28090649
ABSTRACT
Numerous pharmacogenetic clinical guidelines and recommendations have been published, but barriers have hindered the clinical implementation of pharmacogenetics. The Translational Pharmacogenetics Program (TPP) of the National Institutes of Health (NIH) Pharmacogenomics Research Network was established in 2011 to catalog and contribute to the development of pharmacogenetic implementations at eight US healthcare systems, with the goal to disseminate real-world solutions for the barriers to clinical pharmacogenetic implementation. The TPP collected and normalized pharmacogenetic implementation metrics through June 2015, including gene-drug pairs implemented, interpretations of alleles and diplotypes, numbers of tests performed and actionable results, and workflow diagrams. TPP participant institutions developed diverse solutions to overcome many barriers, but the use of Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines provided some consistency among the institutions. The TPP also collected some pharmacogenetic implementation outcomes (scientific, educational, financial, and informatics), which may inform healthcare systems seeking to implement their own pharmacogenetic testing programs.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Guías de Práctica Clínica como Asunto / Atención a la Salud / Investigación Biomédica Traslacional Tipo de estudio: Guideline Aspecto: Determinantes_sociais_saude / Implementation_research Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Clin Pharmacol Ther Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Farmacogenética / Guías de Práctica Clínica como Asunto / Atención a la Salud / Investigación Biomédica Traslacional Tipo de estudio: Guideline Aspecto: Determinantes_sociais_saude / Implementation_research Límite: Humans País/Región como asunto: America do norte Idioma: En Revista: Clin Pharmacol Ther Año: 2017 Tipo del documento: Article País de afiliación: Estados Unidos